Vaccine boost doesn't undermine 'search for yield' thesis
- Pfizer’s successful Covid vaccine trial boosts the prospects for an earlier and faster economic recovery
- This may bring forward the timing and pace of rate hikes globally, but doesn't undermine our 'low for long' view
- The favourable backdrop for EM assets will likely remain for at least the next 12 months
This report is independent investment research as contemplated by COBS 12.2 of the FCA Handbook and is a research recommendation under COBS 12.4 of the FCA Handbook. Where it is not technically a res...